The healthcare provider orders Lovenox 1 mg/kg SQ now. Your patient weighs 198 lbs. The available concentration is Lovenox 30 mg/0.3 mL. How many mL will the patient receive?

Choice A reason: Dry cough is a common, not serious, side effect of ACE inhibitors due to bradykinin accumulation. While bothersome, it’s not life-threatening like angioedema. It often necessitates switching to an ARB, but calling it serious overstates the risk, making this choice incorrect.

Choice B reason: Dry cough occurs in 5-20% of ACE inhibitor users but doesn’t typically subside with continued use, as bradykinin accumulation persists. Patients often require a medication change (e.g., to ARBs), making the claim that it will subside over time inaccurate and incorrect.

Choice C reason: Dry cough is common but not universal in ACE inhibitor users, affecting 5-20% of patients due to variable bradykinin sensitivity. Stating it occurs in all patients is inaccurate, as many tolerate ACE inhibitors without cough, making this choice incorrect.

Choice D reason: Dry cough, caused by bradykinin buildup, affects some ACE inhibitor users and is uncomfortable, often requiring a switch to an ARB, which doesn’t affect bradykinin. This accurately reflects the side effect’s impact and management, making it the correct choice for the nurse’s response.

Choice A reason: A 25-year-old man typically has mature liver and kidney function, efficiently metabolizing and excreting CNS depressants like benzodiazepines. Toxicity risk is lower compared to neonates, whose immature systems impair drug clearance, making this choice less critical for close toxicity monitoring.

Choice B reason: A 15-year-old boy has relatively mature metabolic pathways, though not fully adult-like. CNS depressants are cleared more effectively than in neonates, reducing toxicity risk. Adolescents are less vulnerable than infants to accumulation, making this choice less concerning for drug toxicity observation.

Choice C reason: A 3-week-old neonate has immature liver enzymes (e.g., CYP450) and reduced renal clearance, increasing the risk of CNS depressant toxicity (e.g., respiratory depression, sedation). Their low body mass and underdeveloped metabolism necessitate close monitoring, making this the correct choice for heightened toxicity vigilance.

Choice D reason: A 25-year-old woman, like men of the same age, typically has efficient drug metabolism and excretion. CNS depressants pose lower toxicity risk compared to neonates, whose immature systems lead to drug accumulation, making this choice less critical for close toxicity monitoring.